Clinical data | |
---|---|
Trade names | Sandomigran, Mosegor, Litec, others |
Other names | Pizotyline; BC-105 |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 78% |
Protein binding | 91% |
Metabolism | Glucuronidation (main route). N-glucuronide accounts for >50% of plasma and 60–70% of urinary excreted drug |
Elimination half-life | 23 hours |
Excretion | 18% feces, 55% urine (both as metabolites) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.036.014 |
Chemical and physical data | |
Formula | C19H21NS |
Molar mass | 295.44 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Pizotifen, also known as pizotyline and sold under the brand names Sandomigran and Mosegor among others, is an antimigraine agent of the tricyclic group which is used primarily as a preventative to reduce the frequency of recurrent migraine headaches.[1]